FY2024 EPS Estimates for Zevra Therapeutics, Inc. Reduced by Analyst (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at William Blair cut their FY2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, September 18th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.60) for the year, down from their previous forecast of ($1.58). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.58) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.28 EPS, Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at $0.60 EPS.

Several other research analysts have also issued reports on ZVRA. Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Finally, HC Wainwright increased their target price on Zevra Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.25.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $8.06 on Friday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The company has a market capitalization of $337.34 million, a price-to-earnings ratio of -5.97 and a beta of 1.94. The firm’s 50-day moving average is $7.04 and its 200 day moving average is $5.71.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period in the previous year, the firm earned ($0.15) earnings per share.

Insider Activity

In other news, Director Thomas Anderson acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were bought at an average price of $6.81 per share, with a total value of $68,100.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders purchased 22,000 shares of company stock valued at $140,340. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently made changes to their positions in the company. Jump Financial LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $217,000. Focus Financial Network Inc. ADV bought a new stake in shares of Zevra Therapeutics in the 4th quarter valued at about $141,000. Armistice Capital LLC purchased a new stake in shares of Zevra Therapeutics in the 4th quarter worth approximately $1,755,000. Virtu Financial LLC bought a new position in shares of Zevra Therapeutics during the fourth quarter valued at approximately $177,000. Finally, IFG Advisors LLC increased its holdings in Zevra Therapeutics by 45.0% during the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock valued at $108,000 after buying an additional 5,800 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.